Oncolytics Biotech Inc.
Toronto Stock Exchange ONC.TO
Oncolytics Biotech Inc. Shareholders' Equity for the year ending December 31, 2023
-
Oncolytics Biotech Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 19.55 M, a -31.50% change year over year.
-
Oncolytics Biotech Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 28.54 M, a 46.91% change year over year.
-
Oncolytics Biotech Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 19.43 M, a 23,501.15% change year over year.
-
Oncolytics Biotech Inc. Shareholders' Equity for the year ending December 31, 2019 was USD -83.01 K.
| Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
|---|
Don’t Miss A Beat
| CEO | Mr. Wayne F. Pisano M.B.A. |
| IPO Date | June 1, 2000 |
| Location | Canada |
| Headquarters | 322 11th Avenue SW |
| Employees | 29 |
| Sector | Healthcare |
| Industries | |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Past 5 years
USD 1.52
StockViz Staff
February 6, 2025
Any question? Send us an email